PL2109622T3 - Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B - Google Patents

Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B

Info

Publication number
PL2109622T3
PL2109622T3 PL08712978T PL08712978T PL2109622T3 PL 2109622 T3 PL2109622 T3 PL 2109622T3 PL 08712978 T PL08712978 T PL 08712978T PL 08712978 T PL08712978 T PL 08712978T PL 2109622 T3 PL2109622 T3 PL 2109622T3
Authority
PL
Poland
Prior art keywords
staphylcoccus
enterotoxin
neutralize
high affinity
affinity antibodies
Prior art date
Application number
PL08712978T
Other languages
English (en)
Polish (pl)
Inventor
Philip M. Sass
Nicholas C. Nicolaides
Luigi Grasso
Marc Berger
Tao Sai
Original Assignee
Morphotek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek, Inc. filed Critical Morphotek, Inc.
Publication of PL2109622T3 publication Critical patent/PL2109622T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08712978T 2007-01-03 2008-01-03 Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B PL2109622T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US88840507P 2007-02-06 2007-02-06

Publications (1)

Publication Number Publication Date
PL2109622T3 true PL2109622T3 (pl) 2017-06-30

Family

ID=39529113

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08712978T PL2109622T3 (pl) 2007-01-03 2008-01-03 Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B

Country Status (9)

Country Link
US (6) US8236932B2 (enExample)
EP (2) EP3138852A1 (enExample)
JP (3) JP5412293B2 (enExample)
AU (1) AU2008205376B2 (enExample)
CA (2) CA2674382C (enExample)
DK (1) DK2109622T3 (enExample)
ES (1) ES2619943T3 (enExample)
PL (1) PL2109622T3 (enExample)
WO (1) WO2008085878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674382C (en) 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU3093395A (en) 1994-07-06 1996-01-25 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
EP1127132A1 (en) * 1998-10-07 2001-08-29 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20050240009A1 (en) * 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
JP4571586B2 (ja) * 2003-09-05 2010-10-27 一般財団法人化学及血清療法研究所 プロテアーゼ耐性seb改変体およびそれを含むワクチン
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2674382C (en) * 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b

Also Published As

Publication number Publication date
US20180094048A1 (en) 2018-04-05
US20140072553A1 (en) 2014-03-13
AU2008205376B2 (en) 2012-07-12
US9868780B2 (en) 2018-01-16
EP2109622B1 (en) 2016-11-09
JP2016146824A (ja) 2016-08-18
CA2924155A1 (en) 2008-07-17
US20120171223A1 (en) 2012-07-05
JP5412293B2 (ja) 2014-02-12
WO2008085878A3 (en) 2009-02-26
CA2674382A1 (en) 2008-07-17
US10364284B2 (en) 2019-07-30
WO2008085878A2 (en) 2008-07-17
CA2674382C (en) 2016-05-31
ES2619943T3 (es) 2017-06-27
US20150050276A1 (en) 2015-02-19
US20130183314A1 (en) 2013-07-18
CA2924155C (en) 2020-02-11
US8236932B2 (en) 2012-08-07
JP5881646B2 (ja) 2016-03-09
US8895704B2 (en) 2014-11-25
JP2013216673A (ja) 2013-10-24
DK2109622T3 (en) 2017-02-13
EP2109622A2 (en) 2009-10-21
US20170121396A1 (en) 2017-05-04
EP3138852A1 (en) 2017-03-08
AU2008205376A1 (en) 2008-07-17
JP6195946B2 (ja) 2017-09-13
JP2010514459A (ja) 2010-05-06
US9359428B2 (en) 2016-06-07
US8889846B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
GB0708002D0 (en) Antibodies
GB2451928B (en) Modified Toxins
PL2146745T3 (pl) Pięcioswoiste przeciwciało
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
IL204615A0 (en) Human antibodies that bind mesothelin, and uses thereof
ZA200906345B (en) Anti-sclerostin antibodies
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
IL198592A0 (en) Tes7 and antibodies that bind thereto
ZA201002275B (en) Il-23 antibodies
IL201983A (en) Antibody against pan nrpa
PT2121751T (pt) Anticorpos monoclonais contra angptl3
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0718737D0 (en) Antibodies
GB0615662D0 (en) Antibody
IL205073A0 (en) Anti-bst2 antibody
IL202942A (en) Chromatographic methods
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
IL202996A0 (en) Anti-mcp-1 antibodies, compositions, methods and uses
EP1943526A4 (en) DEVICE FOR RESOLVING RELATIONSHIP BETWEEN PEOPLE
EP2061511A4 (en) MONOCLONAL ANTIBODY OF SMALLPOX
GB0707716D0 (en) Affinity group
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0724185D0 (en) Antibodies